We are live on !
Find out more
C WorldWide Group Portfolio holdings
AUM
$4.15B
Turnover
9.8%
1-Year Est. Return
13.14%
This Fund
S&P 500
This Quarter Est. Return
+9.34%
1 Year Est. Return
+13.14%
3 Year Est. Return
+63.19%
5 Year Est. Return
+70.18%
10 Year Est. Return
+417.82%
AUM
$4.15B
AUM Growth
-$512M
(-11%)
Cap. Flow
-$812M
Cap. Flow % of AUM
Cap. Flow %
-19.59%
Top 10 Holdings %
Top 10 Hldgs %
61.56%
Holding
102
New
5
Increased
22
Reduced
45
Closed
5
Avg Time Held
4.5
years
Top 10 Avg Time Held
4.5
years
Top 20 Avg Time Held
4.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$170M |
| 2 |
Nu Holdings
NU
|
+$61.8M |
| 3 |
Republic Services
RSG
|
+$26.9M |
| 4 |
NextEra Energy
NEE
|
+$13.1M |
| 5 |
Insmed
INSM
|
+$12.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$257M |
| 2 |
Intercontinental Exchange
ICE
|
+$153M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$144M |
| 4 |
Uber
UBER
|
+$98.3M |
| 5 |
Amazon
AMZN
|
+$63.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.35% |
| 2 | Technology | 17.66% |
| 3 | Healthcare | 14.52% |
| 4 | Industrials | 11.76% |
| 5 | Consumer Discretionary | 10.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Royalty Pharma
RPRX
$28.9B
| $26.5M | 0.64% |
471,881
-189,895
| -29% | -$9.9M |
2025 Q1
5 quarters
|
|
27
Elevance Health
ELV
$89.9B
| $25.1M | 0.61% |
65,000
| – | – |
2017 Q3
35 quarters
|
|
28
Trip.com Group
TCOM
$24.3B
| $24.4M | 0.59% |
613,630
+12,463
| +2% | +$618K |
2021 Q1
21 quarters
|
|
29
Vertex Pharmaceuticals
VRTX
$134B
| $22.9M | 0.55% |
46,057
| – | – |
2014 Q3
47 quarters
|
|
30
Penumbra
PEN
$12.5B
| $22.7M | 0.55% |
72,000
| – | – |
2024 Q1
9 quarters
|
|
31
Krystal Biotech
KRYS
$9.5B
| $21.5M | 0.52% |
57,809
-10,000
| -15% | -$2.99M |
2020 Q1
25 quarters
|
|
32
Neurocrine Biosciences
NBIX
$14.8B
| $21.1M | 0.51% |
125,000
| – | – |
2024 Q2
8 quarters
|
|
33
Service Corp International
SCI
$11.2B
| $20.1M | 0.48% |
264,157
+34,727
| +15% | +$2.72M |
2019 Q4
26 quarters
|
|
34
Medtronic
MDT
$121B
| $19.9M | 0.48% |
255,000
| – | – |
2023 Q4
10 quarters
|
|
35
Sea Limited
SE
$46B
| $19M | 0.46% |
198,560
+4,953
| +3% | +$435K |
2020 Q1
25 quarters
|
|
36
Synopsys
SNPS
$92.3B
| $16.6M | 0.4% |
37,250
-115
| -0.3% | -$54.1K |
2020 Q3
23 quarters
|
|
37
Meta Platforms (Facebook)
META
$1.59T
| $15.9M | 0.38% |
28,283
-3,762
| -12% | -$2.3M |
2025 Q3
3 quarters
|
|
38
Privia Health
PRVA
$2.79B
| $15.7M | 0.38% |
610,000
| – | – |
2022 Q2
16 quarters
|
|
39
BioMarin Pharmaceuticals
BMRN
$10.8B
| $15.3M | 0.37% |
267,851
| – | – |
2014 Q3
47 quarters
|
|
40
Insulet
PODD
$10.3B
| $15.2M | 0.37% |
99,908
| – | – |
2014 Q3
47 quarters
|
|
41
NovoCure
NVCR
$1.65B
| $14.7M | 0.36% |
971,784
| – | – |
2017 Q2
36 quarters
|
|
42
Align Technology
ALGN
$10.9B
| $14.1M | 0.34% |
83,428
| – | – |
2019 Q2
28 quarters
|
|
43
Waters Corp
WAT
$46.9B
| $13.6M | 0.33% |
36,321
-121
| -0.3% | -$41.3K |
2020 Q3
23 quarters
|
|
44
MSCI
MSCI
$44B
| $13.5M | 0.33% |
24,132
-76
| -0.3% | -$44.3K |
2019 Q2
28 quarters
|
|
45
Alkermes
ALKS
$7.59B
| $13.1M | 0.32% |
250,000
| – | – |
2024 Q4
6 quarters
|
|
46
Clean Harbors
CLH
$16.5B
| $12.7M | 0.31% |
42,397
-7,474
| -15% | -$2.21M |
2024 Q2
8 quarters
|
|
47
Ferguson
FERG
$44.6B
| $12.5M | 0.3% |
52,568
-170
| -0.3% | -$41K |
2022 Q3
15 quarters
|
|
48
Hesai Group
HSAI
$2.17B
| $12.4M | 0.3% |
679,558
+9,385
| +1% | +$192K |
2025 Q3
3 quarters
|
|
49
Boston Scientific
BSX
$61.5B
| $12M | 0.29% |
280,000
+100,000
| +56% | +$5.43M |
2026 Q1
1 quarter
|
|
50
ResMed
RMD
$35.2B
| $11.7M | 0.28% |
59,987
+4,048
| +7% | +$839K |
2020 Q3
23 quarters
|
|
Similar funds
C WorldWide Group's Q2 2026 Portfolio in Review
As of Q2 2026, C WorldWide Group held 102 positions worth $4.15B, down 11% from $4.66B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
C WorldWide Group withdrew a net $812M in Q2 2026, closing 5 positions and reducing 45 holdings. Its most notable exit was Uber, an estimated $98.3M position sold in full.
By sector, the portfolio is most concentrated in Financials at 23% of assets, down from 25% a quarter earlier, followed by Technology and Healthcare.
Against the trend, C WorldWide Group opened a new position in Broadcom worth $160M.
- C WorldWide Group's largest Q2 2026 buy was Broadcom: 424,815 shares worth $160M.
- C WorldWide Group added most to Nu Holdings in Q2 2026, an estimated $61.8M increase.
- C WorldWide Group's biggest Q2 2026 reduction was Thermo Fisher Scientific, cutting an estimated $257M.
- C WorldWide Group fully exited Uber in Q2 2026, selling an estimated $98.3M.
- C WorldWide Group's ten largest holdings make up 62% of its $4.15B portfolio in Q2 2026.
- C WorldWide Group opened 5 new positions and closed 5 in Q2 2026.
- C WorldWide Group's portfolio value fell 11% quarter-over-quarter to $4.15B.
Based on C WorldWide Group's 13F filing for Q2 2026, filed 4 Aug 2026.